Navidea Biopharmaceuticals Files for Chapter 11 Bankruptcy, Ending Years of Financial Struggle
Ohio-based diagnostic and immunotherapy biopharma Navidea Biopharmaceuticals has filed for Chapter 11 bankruptcy protection, marking the latest — and likely final — chapter in the company’s long financial struggles.
In a brief statement, Navidea said the filing is intended to allow an “orderly restructuring of its financial obligations” while maintaining limited operations to preserve value for creditors and stakeholders. The company also plans to “evaluate strategic alternatives, protect its assets, and ensure fair treatment of creditors” during the process.
The bankruptcy follows several years of setbacks. Navidea was delisted from the New York Stock Exchange in 2022, and its appeal was rejected in 2023. The company also spent years entangled in legal disputes, including a protracted case with Capital Royalty Partners that was finally settled in 2023. Last year, Navidea filed a Form 15 to suspend SEC reporting requirements, signaling a deeper financial retreat.
Navidea’s lone commercial product, Lymphoseek (technetium Tc 99m tilmanocept), is a radiopharmaceutical agent used in lymphatic mapping to track cancer spread. The company sold North American rights to Cardinal Health in 2017 for $83 million upfront, with up to $227 million in potential milestone payments through 2026.
Despite years of effort, Navidea has struggled to expand beyond Lymphoseek. Its development pipeline — which once included imaging diagnostics for arthritis and cardiovascular diseases — has failed to produce market-ready candidates. The company had also been seeking a commercial partner to market Lymphoseek in Europe.
The bankruptcy filing effectively caps a years-long struggle for viability for the once-promising biopharma, which now faces the challenge of restructuring its remaining assets and obligations under court supervision.
